Facebook Twitter YouTube Google Plus

T.) Treatment Options for Patients with Recurrent Disease after HIPEC, HRA - Panel Discussion

H. Richard Alexander, MD
University of Maryland School of Medicine

Dr. Richard Alexander is an internationally recognized surgical oncologist and cancer researcher. He treats patients at the University of Maryland Marlene and Stewart Greenebaum Cancer Center and is associate chairman for clinical research in the Department of Surgery of the University of Maryland School of Medicine in Baltimore. Dr. Alexander is recognized for developing innovative techniques to treat patients with regionally advanced cancers of the extremity, peritoneum, or liver.  His laboratory is focused on identifying new therapeutic interventions based on elucidating the molecular profiles and cellular pathways that are activated in peritoneal mesothelioma.

Dr. Alexander received his medical degree from the Georgetown University School of Medicine. He completed his residency in general surgery at the National Naval Medical Center in Bethesda and did a fellowship in surgical oncology at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Alexander has written more than 220 journal articles and has lectured throughout the United States and the world.

Claire F. Verschraegen, MD
University of New Mexico

Dr. Claire Verschraegen is currently the Director of Translational Therapeutics at the Cancer Research and Treatment Center of the University of New Mexico. Dr. Verschraegen was on the faculty at M. D. Anderson Cancer Center for seven years before moving to New Mexico. At M. D. Anderson, she became known has a specialist for gynecological cancers, appendiceal cancers, and mesothelioma, studying new anticancer drugs for these diseases. At the University of New Mexico Cancer Research and Treatment Center, she built the Clinical Trial Office and served as the medical director of the New Mexico Cancer Care Alliance, which promotes clinical trials in the community. She is now the Director of the Translational Therapeutics program and continues her clinical research activities in drug development for gynecological cancers and rare malignancies.

John Chabot, MD
Columbia University Medical Center

Dr John Chabot is the Vice Chair for General Surgery and Division Chief, GI/Endocrine Surgery at the NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY. Dr. Chabot is responsible for the surgical management of patients with malignant peritoneal mesothelioma.  His current research involves the use of surgery, intraperitoneal chemotherapy and immunotherapy in treating peritoneal mesothelioma.   


To view this video, please click on the image below.

© 2009 Mesothelioma Applied Research Foundation, Inc. All rights reserved. 501(c)(3)

A.) Effective Advocacy and the Case for Federal Meso Research Funding

B.) State Assistance on Insurance Appeals

C.) Cancer Genetics in the Mesothelioma Family

D.) Fundraising

E.) Navigating Mesothelioma Clinical Trials with GPS (Getting Personalized Service)

F.) Update from Across the Pond

G.) The Mesothelioma Experience: Patient and Provider Perspectives Panel

H.) Work of the Science Advisory Board

J.) Present and Future of Mesothelioma Treatment: Medical Oncologist and Researcher Perspective

K.) New Developments in Radiation Oncology: A Global Perspective

M.) Pain Management

Mesothelioma Treatment: Present & Future from a Surgeon & Research Perspective | Dr. Harvey Pass

N.) Traditional Healing with Modern Science

O.) Update on Clinical Trials and Mesothelioma Research

P.) Mesothelioma Tissue Bank

Photodynamic Therapy for Mesothelioma Treatment | Dr. Joseph Friedberg

Q.) EGFR Inhibitors for Patients with Malignant Peritoneal Mesothelioma

R.) The Use of Cytokine Inhibitors: Translational Lab Results

S.) Identifying and Targeting Aggressive Malignant Peritoneal Mesothelioma: Morphologic and Molecular Studies

T.) Treatment Options for Patients with Recurrent Disease after HIPEC, HRA - Panel Discussion